To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
The Health, Labor and Welfare Ministry on Friday gave fast-track approval to the inoculation of children aged 5 to 11 with a coronavirus vaccine from U.S. pharmaceutical firm Pfizer Inc.
The ministry is set to make it a “temporary vaccination” at public expense after deliberation at a panel of experts to be held Wednesday. The government plans to start vaccinating about 7.15 million children as early as March, and is considering bringing forward that schedule, too.
The Pfizer vaccine is currently given to people aged 12 or older in Japan. The vaccine for children aged 5 to 11 is adjusted by reducing the amount of ingredients to one-third of that for those aged 12 or older, and giving two doses three weeks apart.
The vaccines will begin being imported in February, and the government is considering whether to speed up the delivery schedule to local governments.
Prime Minister Fumio Kishida said at a House of Representatives interpellation on Thursday, “We’ll start vaccinations for those who wish to have them as soon as completing the necessary procedures.”
According to Pfizer, a clinical trial conducted overseas on about 2,000 children aged 5 to 11 confirmed that the vaccine had a 90.7% efficacy rate in preventing the onset of the disease. However, the study was conducted last summer, when the delta variant of the coronavirus was dominant, and there is not enough data on the efficacy of the omicron variant. Even so, the Japan Pediatric Society said the vaccination was expected to prevent the disease from becoming severe.
According to the U.S. Centers for Disease Control and Prevention, about 8.7 million vaccinations had been administered to 5-to-11-year-olds in the United States as of mid-December last year, with 4,249 cases of suspected adverse reactions reported. Of them, 100 were serious, including high fever and vomiting.
In Europe and the United States, vaccinations for children aged 5 to 11 began around November last year. The United States and Israel recommend vaccination for all children, while Germany specifically recommends it for children with underlying health conditions who are at high risk of severe illness.
In Japan, an omicron outbreak has led to an increase in infections among children below vaccination age. The weekly number of infections among those under 10 was around 100 in November and December last year, but has risen sharply since the end of the year, to 12,947 in the week of Jan. 12-18.
